Resources | XARELTO® (rivaroxaban) HCP

For your practice

Downloads

Updated AF guideline flashcardDownload 2023 guideline recommendations

2024 ACC/AHA/Multisociety PAD Guideline pocket guide2024 ACC/AHA/Multisociety Guideline for the management of lower extremity PAD pocket guide

Updated CAD guideline flashcard2023 AHA/ACC/ACCP/ASPC/NLA/
PCNA Guideline for the management of patients with CCD

US Prescribing informationDownload the full prescribing information for XARELTO®

Dosing guideGet the complete guide to dosing for XARELTO®

XARELTO® Patient ResourcesTools that may help your patients start and stay on therapy

ACC = American College of Cardiology; ACCP = American College of Clinical Pharmacy; AF = atrial fibrillation; AHA = American Heart Association; ASPC = American Society of Preventive Cardiology; CAD = coronary artery disease; CCD = chronic coronary disease; IUA = International Union of Angiology; NLA = National Lipid Association; PAD = peripheral artery disease; PCNA = Preventive Cardiovascular Nurses Association; US = United States; VTE = venous thromboembolism.

Requests

Request SamplesRequest samples for your office today

Starter Pack for DVT/PE30-day Starter Pack after 6 months of initial treatment

DVT = deep vein thrombosis; PE = pulmonary embolism.

For your patients

Patient savings and support

XARELTO WithMe
Savings and SupportXARELTO withMe supports your patients throughout the treatment journey

Patient Affordability OptionsYour patient's guide to learning about sources of cost support

Patient welcome kits

NVAF Patient Welcome
Kit BrochureYour patient’s guide to starting treatment for NVAF

DVT/PE Patient
Welcome Kit BrochureYour patient’s guide to starting treatment for DVT/PE

CAD/PAD Patient BrochureYour patient's guide to starting treatment for CAD/PAD

ORS Patient Welcome
Kit BrochureYour patient’s guide to starting treatment for ORS

CAD = coronary artery disease; DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; ORS = orthopedic replacement surgery; PAD = peripheral artery disease;
PE = pulmonary embolism.

Select XARELTO® reprints

NVAF

Rocket AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial

PK/PD, and Safety of
Single-Dose XARELTO®Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

AF = atrial fibrillation; NVAF = nonvalvular atrial fibrillation; PD = pharmacodynamics; PK = pharmacokinetics.

CAD

COMPASSEikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease

COMPASS (CAD Subgroup)Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial

COMPASS (Risk
Stratification)Anand SS et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial

COMPASS (Diabetes Subgroup)Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease

CAD = coronary artery disease.

PAD

COMPASS (PAD Subgroup)Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial

VOYAGER (PAD)Bonaca MP et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix]

PAD = peripheral artery disease.

VTE Prophylaxis

Magellan (Subgroup)
for Acutely Ill Medical
PatientsSpyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

VTE = venous thromboembolism.

DVT/PE Initial

EINSTEIN DVTThe EINSTEIN Investigators. Oral rivaroxaban for symptomatic VTE

EINSTEIN PEThe EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic PE

Pooled EINSTEIN DVT and PEPrins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic VTE: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies

EINSTEIN Cancer SubgroupsPrins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic VTE in patients with cancer (EINSTEIN DVT and EINSTEIN PE)

DVT = deep vein thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.

DVT/PE Extended

EINSTEIN CHOICEEINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of VTE

PE = pulmonary embolism; VTE = venous thromboembolism.

DVT/PE Prophylaxis

RECORD1DVT prophylaxis after hip replacement surgery. Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

RECORD2Extended DVT prophylaxis after hip replacement surgery.Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of VTE after total hip arthroplasty: a double-blind, randomized controlled trial

RECORD3DVT prophylaxis after knee replacement surgery.Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

DVT = deep vein thrombosis; PE = pulmonary embolism;
VTE = venous thromboembolism.